Artiva Biotherapeutics, Inc.
ARTV Healthcare Biotechnology
Artiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023. In the quarter to June 2026, EPS grew 27.6% and free cash flow grew 13.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ARTV
Artiva Biotherapeutics, Inc. (ARTV) P/E ratio
Artiva Biotherapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.3× (April 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2024 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SRZN Surrozen, Inc. compare | n/m |
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| FULC Fulcrum Therapeutics, Inc. compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| BNTC Benitec Biopharma Limited compare | n/m |
| OCGN Ocugen, Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. | n/m |
| ARCT Arcturus Therapeutics Holdings Inc. compare | n/m |
| AGEN Agenus Inc. compare | 2.3× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)